Decrease of muscle strength. Muscle wasting and atrophy, not elsewhere classified
Conditions
Interventions
Intervention 1: Dietary Magnesium supplement, 250 mg, for 8 weeks. Intervention 2: Placebo, the same tablets as the active drug with the same dose for 8 weeks.
Prevention
Placebo
Dietary Magnesium supplement, 250 mg, for 8 weeks
Placebo, the same tablets as the active drug with the same dose for 8 weeks
Sponsors
Iran Univesity of Medical Sciences
Eligibility
Sex/Gender
Female
Age
45 Years to 55 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1. Age 45 to 55 years old 2. Stopped menstrual cycle for at least 12 month 3. Voluntary participation Exclusion criteria: 1. BMI less than 25 Kg/m2 2. Having one of the following diseases: uncontrolled hypertension, Diabetes, cardiovascular diseases, asthma, Thyroid or parathyroid diseases, renal disorders, liver diseases, bone or rheumatoid disorders, gastrointestinal diseases, and infectious diseases 3. Taking any supplements including minerals, vitamins, and ?-3 fatty acids 4. Receiving hormonal products 5. Cigarette smoking 6. Using one of the following medications: anti-inflammatory drugs (including NSAIDs, steroids, salicylates), aminoglycosides antibiotics, Laxative drug, magnesium-containing drugs 7. compliance less than 70%
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Muscle strength in hand and foot. Timepoint: 8 weeks. Method of measurement: Dynamometer, Handgrip. | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflamentory markers. Timepoint: 8 weeks after intervention. Method of measurement: decline of inflamentory marker. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed